Today’s European Commission approval is the second worldwide; in the U.S., more than 33,000 patients have been treated with Veltassa since it was approved by the FDA in 2015 Patients with advanced ...

WILMINGTON, Del.--(BUSINESS WIRE)-- Today, the US Food and Drug Administration (FDA) approved a label update in the US for AstraZeneca’s LOKELMA® (sodium zirconium cyclosilicate) to include a dosing ...

Please provide your email address to receive an email when new articles are posted on . Hyperkalemia associated with renin-angiotensin-aldosterone system inhibitors therapy can be effectively managed.

A recent population-based study assessed the incidence of clinically significant hyperkalemia among adult CKD patients being treated with RAASis and how this affected future treatment. In the study, 9 ...

Lokelma (sodium zirconium cyclosilicate) is a brand-name drug that’s prescribed to treat high potassium levels in adults. As with other drugs, Lokelma can cause side effects, such as fluid retention.

Solution/Product: Patiromer, or RLY5016, is a non-absorbed oral potassium binder being developed for the treatment of hyperkalemia in patients with chronic kidney disease, diabetes and heart failure.

Hyperkalemia is a serious, often life threatening complication of diabetes-related kidney disease. This is one of the most common electrolyte imbalances experienced by people with kidney disease, or ...

Hyperkalemia treatment trends in the ED are varied and inconsistent, depending on potassium levels when patients reach the ED. Although various treatments decreased potassium over 4 hours, only ...

Dublin, March 19, 2021 (GLOBE NEWSWIRE) -- The "Hyperkalemia - Market Insight, Epidemiology and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering. This report ...

Treatment for hyperkalemia varies according to severity. In acute hyperkalemia, which often results from a particular event, such as trauma, doctors may use dialysis and intravenous medications to ...

WILMINGTON, Del.--(BUSINESS WIRE)--Today, the US Food and Drug Administration (FDA) approved a label update in the US for AstraZeneca’s LOKELMA ® (sodium zirconium cyclosilicate) to include a dosing ...